Analysts have been eager to weigh in on the Healthcare sector with new ratings on Illumina (ILMN – Research Report), Cardinal Health (CAH – Research Report) and Beam Therapeutics (BEAM – Research Report).
Morgan Stanley analyst Tejas Savant maintained a Hold rating on Illumina today and set a price target of $225.00. The company’s shares closed last Monday at $215.91.
According to TipRanks.com, Savant is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Illumina with a $254.00 average price target, representing a 13.6% upside. In a report issued on November 4, Robert W. Baird also maintained a Hold rating on the stock with a $210.00 price target.
Cardinal Health (CAH)
In a report released today, Erin Wright from Morgan Stanley maintained a Buy rating on Cardinal Health, with a price target of $82.00. The company’s shares closed last Monday at $81.21.
According to TipRanks.com, Wright is a 5-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Cardinal Health with a $75.50 average price target.
Beam Therapeutics (BEAM)
SVB Securities analyst Mani Foroohar maintained a Buy rating on Beam Therapeutics today and set a price target of $81.00. The company’s shares closed last Monday at $38.91, close to its 52-week low of $27.77.
According to TipRanks.com, Foroohar is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Beam Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $77.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ILMN:
- GreenLight Biosciences to Participate in Upcoming Investor Conferences in November
- Meta Stock: Why It Jumped and Where It’s Headed
- Cassava Sciences (SAVA) Gets a Buy from JonesTrading
- CORRECTION — BIO-key, Provider of Identity Access Management (IAM) and Biometric Cybersecurity Solutions, Hosts Q3 Investor Call Tues, November 15th at 10am ET
- JonesTrading Remains a Buy on Ocuphire Pharma (OCUP)